Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch
  

Alkermes Pharma Ireland Limited patents

Recent patent applications related to Alkermes Pharma Ireland Limited. Alkermes Pharma Ireland Limited is listed as an Agent/Assignee. Note: Alkermes Pharma Ireland Limited may have other listings under different names/spellings. We're not affiliated with Alkermes Pharma Ireland Limited, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Alkermes Pharma Ireland Limited-related inventors




Date Alkermes Pharma Ireland Limited patents (updated weekly) - BOOKMARK this page
08/17/17 new patent  Compositions of multiple aripiprazole prodrugs
08/03/17Methods for treating depressive symptoms
07/27/17Polymorphic forms of naltrexone
07/13/17Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
07/13/17Pharmaceutical compositions comprising sorbitan esters
06/15/17Sustained release aminopyridine composition
06/08/17Aripiprazole formulations having increased injection speeds
05/18/17Opioid agonist antagonist combinations
05/11/17Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
05/04/17Methods for treating antipsychotic-induced weight gain
04/27/17Morphinan derivatives with high oral bioavailability
04/06/17Prodrugs of fumarates and their use in treating various diseases
03/02/17Compositions of buprenorphine and u antagonists
03/02/17Polymer-based sustained release device
02/02/17Sustained release aminopyridine composition
01/19/17Prodrugs of nh-acidic compounds
12/15/16Polymorphic forms of naltrexone
11/10/16Morphan and morphinan analogues, and methods of use
11/10/16Sustained release aminopyridine composition
11/03/16Heterocyclic compounds for the treatment of neurological and psychological disorders
09/15/16Aripiprazole formulations having increased injection speeds
09/08/16Compositions of buprenorphine and u antagonists
08/11/16Reduction of flake-like aggregation in nanoparticulate active agent compositions
08/11/16Monomethylfumarate prodrug compositions
08/11/16Reduction of flake-like aggregation in nanoparticulate active agent compositions
08/11/16Reduction of flake-like aggregation in nanoparticulate active agent compositions
06/23/16Sustained release aminopyridine composition
05/19/16Pharmaceutical compositions having improved storage stability
05/19/16Polymorphic forms of naltrexone
05/19/16Prodrugs of fumarates and their use in treating various diseases
04/21/16Drug delivery device
03/24/16Sustained release aminopyridine composition
03/17/16Abuse resistant pharmaceutical compositions
03/17/16Abuse resistant pharmaceutical compositions
02/25/16Morphinan derivatives for the treatment of drug overdose
02/25/16Methods for treating antipsychotic-induced weight gain
02/25/16Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
02/18/16Aripiprazole prodrug compositions
02/11/16Pharmaceutical compositions comprising sorbitan esters
01/28/16Multi-api loading prodrugs
01/28/16Process for synthesizing oxidized lactam compounds
01/14/16Prodrugs of heteraromatic compounds
12/31/15Morphan and morphinan analogues, and methods of use
12/31/15Prodrugs of nh-acidic compounds
11/12/15Nanoparticulate megestrol formulations
11/12/15Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
10/08/15Drug delivery composition
10/01/15Heterocyclic compounds for the treatment of neurological and psychological disorders
09/24/15Aripiprazole formulations having increased injection speeds
09/17/15Pharmaceutical compositions comprising sorbitan esters
08/27/15Injectable nanoparticulate olanzapine formulations
08/27/15Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
08/06/15Nanoparticulate cinacalcet compositions
07/30/15Prodrugs of secondary amine compounds
04/02/15Morphinan derivatives with high oral bioavailability
03/26/15Nanoparticulate megestrol formulations
03/12/15Methods for treating depressive symptoms
02/26/15Nanoparticulate megestrol formulations
02/26/15Nanoparticulate megestrol formulations
02/19/15Compositions of buprenorphine and μ antagonists
02/12/15Morphan and morphinan analogues, and methods of use
10/09/14Process for the synthesis of substituted morphinans
09/18/14Prodrugs of fumarates and their use in treating various diseases
09/04/14Alcohol resistant enteric pharmaceutical compositions
08/21/14Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer
Patent Packs
08/07/14Prodrugs of nh-acidic compounds
04/17/14Reduction of flake-like aggregation in nanoparticulate active agent compositions
04/03/14Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
03/27/14Polymer-based sustained release device
03/27/14Pharmaceutical compositions having improved storage stability
02/20/14Process for synthesizing oxidized lactam compounds
01/30/14Polymer-based sustained release device
01/16/14Sustained release aminopyridine composition
11/21/13Injectable nanoparticulate olanzapine formulations
10/10/13Pharmaceutical compositions comprising fatty acid esters
10/10/13Pharmaceutical compositions comprising fatty glycerol esters
10/10/13Pharmaceutical compositions comprising benzyl alcohol
09/26/13Low viscosity liquid dosage forms
08/29/13Nanoparticulate compositions having lysozyme as a surface stabilizer
07/25/13Compositions of buprenorphine and µ antagonists
Patent Packs
07/18/13Prodrugs of secondary amine compounds
05/23/13Polymer-based sustained release device
04/18/13Heterocyclic compounds for the treatment of neurological and psychological disorders
03/28/13Drug delivery device
02/21/13Sustained release aminopyridine composition
01/10/13Controlled release nanoparticulate compositions
01/10/13Drug delivery device
01/10/13Drug delivery device
01/10/13Drug delivery device
01/10/13Drug delivery device
01/03/13Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
12/13/12Injectable nanoparticulate olanzapine formulations
08/23/12Dry powder aerosols of nanoparticulate drugs







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Alkermes Pharma Ireland Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Alkermes Pharma Ireland Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';